Archaeal lipid mucosal vaccine adjuvant and delivery system

References

• Jakobsen H, Jonsdottir I. Mucosal vaccination against encapsulated respiratory bacteria – new potentials for conjugate vaccines? Scand. J. Immunol.58(2), 119–128 (2003).
   PubMed Web of Science ®Google Scholar
• Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine25(30), 5467–5484 (2007).
   PubMed Web of Science ®Google Scholar
• Mestecky J, Moldoveanu Z, Michalek SM et al. Current opinions for vaccine delivery systems by mucosal routes. J. Control. Release48, 243–257 (1997).
   Web of Science ®Google Scholar
• Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol.6(2), 148–158 (2006).
   PubMed Web of Science ®Google Scholar
• Singh M, O’Hagan DT. Recent advances in vaccine adjuvants. Pharm. Res.19(6), 715–728 (2002).
   PubMed Web of Science ®Google Scholar
• Davis SS. Nasal vaccines. Adv. Drug Deliv. Rev.51(1–3), 21–42 (2001).
   PubMed Web of Science ®Google Scholar
• Mestecky J, Nguyen H, Czerkinsky C, Kiyono H. Oral immunization: an update. Curr. Opin. Gastroenterol.24(6), 713–719 (2008).
   PubMed Web of Science ®Google Scholar
• De Magistris MT. Mucosal delivery of vaccine antigens and its advantages in pediatrics. Adv. Drug Deliv. Rev.58(1), 52–67 (2006).
   PubMed Web of Science ®Google Scholar
• Goyal AK, Khatri K, Mishra N, Vyas SP. New patents on mucosal delivery of vaccines. Expert Opin. Ther. Pat.18(11), 1271–1288 (2008).
   Web of Science ®Google Scholar
• Mann JF, Acevedo R, Campo JD, Perez O, Ferro VA. Delivery systems: a vaccine strategy for overcoming mucosal tolerance? Expert Rev. Vaccines8(1), 103–112 (2009).
   PubMed Web of Science ®Google Scholar
• Mitragotri S. Immunization without needles. Nat. Rev. Immunol.5(12), 905–916 (2005).
   PubMed Web of Science ®Google Scholar
• Freytag LC, Clements JD. Mucosal adjuvants. Vaccine23(15), 1804–1813 (2005).
   PubMed Web of Science ®Google Scholar
• Holmgren J, Czerkinsky C, Eriksson K, Harandi AM. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine21(Suppl. 2), S89–S95 (2003).
   PubMed Web of Science ®Google Scholar
• Yuki Y, Kiyono H. New generation of mucosal adjuvants for the induction of protective immunity. Rev. Med. Virol.13(5), 293–310 (2003).
   PubMed Web of Science ®Google Scholar
• Fujihashi K, Kiyono H. Mucosal immunosenescence: new developments and vaccines to control infectious diseases. Trends Immunol.30(7), 334–343 (2009).
   PubMed Web of Science ®Google Scholar
• Ryan EJ, Daly LM, Mills KHG. Immunomodulators and delivery systems for vaccination by mucosal routes. Trends Biotechnol.19(8), 293–304 (2001).
   PubMed Web of Science ®Google Scholar
• Giudice EL, Campbell JD. Needle-free vaccine delivery. Adv. Drug Deliv. Rev.58(1), 68–89 (2006).
   PubMed Web of Science ®Google Scholar
• Lemoine D, Francotte M, Preat V. Nasal vaccines. From fundamental concepts to vaccine development. STP Pharma Sci.8(1), 5–18 (1998).
   Google Scholar
• Perrie Y, Kirby D, Bramwell VW, Mohammed AR. Recent developments in particulate-based vaccines. Recent Pat. Drug Deliv. Formul.1(2), 117–129 (2007).
   PubMedGoogle Scholar
• Ogra PL, Faden H, Welliver RC. Vaccination strategies for mucosal immune responses. Clin. Microbiol. Rev.14(2), 430–445 (2001).
   PubMed Web of Science ®Google Scholar
• Demberg T, Robert-Guroff M. Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design. Int. Rev. Immunol.28(1), 20–48 (2009).
   PubMed Web of Science ®Google Scholar
• Vajdy M, Srivastava I, Polo J, Donnelly J, O’Hagan D, Singh M. Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines. Immunol. Cell Biol.82(6), 617–627 (2004).
   PubMed Web of Science ®Google Scholar
• Baumann U. Mucosal vaccination against bacterial respiratory infections. Expert Rev. Vaccines7(8), 1257–1276 (2008).
   PubMed Web of Science ®Google Scholar
• Kemble G, Greenberg H. Novel generations of influenza vaccines. Vaccine21(16), 1789–1795 (2003).
   PubMed Web of Science ®Google Scholar
• Oliveira ML, Areas AP, Ho PL. Intranasal vaccines for protection against respiratory and systemic bacterial infections. Expert Rev. Vaccines6(3), 419–429 (2007).
   PubMed Web of Science ®Google Scholar
• Vyas SP, Gupta PN. Implication of nanoparticles/microparticles in mucosal vaccine delivery. Expert Rev. Vaccines6(3), 401–418 (2007).
   PubMed Web of Science ®Google Scholar
• Christensen D, Korsholm KS, Rosenkrands I, Lindenstrom T, Andersen P, Agger EM. Cationic liposomes as vaccine adjuvants. Expert Rev. Vaccines6(5), 785–796 (2007).
   PubMed Web of Science ®Google Scholar
• Giri PK, Khuller GK. Is intranasal vaccination a feasible solution for tuberculosis? Expert Rev. Vaccines7(9), 1341–1356 (2008).
   PubMed Web of Science ®Google Scholar
• Perez O, Lastre M, Cabrera Oet al. New vaccines require potent adjuvants like AFPL1 and AFCo1. Scand. J. Immunol.66(2–3), 271–277 (2007).
   PubMed Web of Science ®Google Scholar
• Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol.30(1), 23–32 (2009).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Rappuoli R. Novel approaches to vaccine delivery. Pharm. Res.21(9), 1519–1530 (2004).
   PubMed Web of Science ®Google Scholar
• Garcon N, Chomez P, Van Mechelen M. Glaxosmithkline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines6(5), 723–739 (2007).
   PubMed Web of Science ®Google Scholar
• Aguilar JC, Rodriguez EG. Vaccine adjuvants revisited. Vaccine25(19), 3752–3762 (2007).
   PubMed Web of Science ®Google Scholar
• Byrd W, Cassels FJ. Intranasal immunization of BALB/c mice with enterotoxigenic Escherichia coli colonization factor CS6 encapsulated in biodegradable poly (dl-lactide-co-glycolide) microspheres. Vaccine24(9), 1359–1366 (2006).
   PubMed Web of Science ®Google Scholar
• Drane D, Gittleson C, Boyle J, Maraskovsky E. ISCOMATRIX™ adjuvant for prophylactic and therapeutic vaccines. Expert Rev. Vaccines6(5), 761–772 (2007).
   PubMed Web of Science ®Google Scholar
• Stephenson I, Zambon MC, Rudin Aet al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J. Virol.80(10), 4962–4970 (2006).
   PubMed Web of Science ®Google Scholar
• Perrie Y, Mohammed AR, Kirby DJ, McNeil SE, Bramwell VW. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int. J. Pharm.364(2), 272–280 (2008).
   PubMed Web of Science ®Google Scholar
• Patel GB, Ponce A, Zhou H, Chen W. Safety of intranasally administered archaeal lipid mucosal vaccine adjuvant and delivery (AMVAD) vaccine in mice. Int. J. Toxicol.27, 329–339 (2008).
   PubMed Web of Science ®Google Scholar
• Patel GB, Ponce A, Zhou H, Chen W. Structural characterization of archaeal lipid mucosal vaccine adjuvant and delivery (AMVAD) formulations prepared by different protocols and their efficacy upon intranasal immunization of mice. J. Liposome Res.18(2), 127–143 (2008).
   PubMed Web of Science ®Google Scholar
• Patel GB, Zhou H, Ponce A, Chen W. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines. Vaccine25(51), 8622–8636 (2007).
   PubMed Web of Science ®Google Scholar
• Kates M. Archaebacterial lipids: structure, biosynthesis and function. Biochem. Soc. Symp.58, 51–72 (1992).
   PubMedGoogle Scholar
• Sprott GD. Structures of archaebacterial membrane lipids. J. Bioenerg. Biomembr.24(6), 555–566 (1992).
   PubMed Web of Science ®Google Scholar
• Patel GB, Sprott GD. Archaeobacterial ether lipid liposomes (archaeosomes) as novel vaccine and drug delivery systems. Crit. Rev. Biotechnol.19(4), 317–357 (1999).
   PubMed Web of Science ®Google Scholar
• Krishnan L, Sprott GD. Archaeosome adjuvants: immunological capabilities and mechanism (s) of action. Vaccine26(17), 2043–2055 (2008).
   PubMed Web of Science ®Google Scholar
• Koga Y, Morii H. Recent advances in structural research on ether lipids from archaea including comparative and physiological aspects. Biosci. Biotechnol. Biochem.69(11), 2019–2034 (2005).
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov.4(2), 145–160 (2005).
   PubMed Web of Science ®Google Scholar
• Sprott GD, Dicaire CJ, Fleming LP, Patel GB. Stability of liposomes prepared from archaeobacterial lipids and phosphatidylcholine mixtures. Cell Mater.6, 143–155 (1996).
   Google Scholar
• Patel GB, Chen W. Archaeosome immunostimulatory vaccine delivery system. Curr. Drug Deliv.2(4), 407–421 (2005).
   PubMedGoogle Scholar
• Choquet CG, Patel GB, Beveridge TJ, Sprott GD. Stability of pressure-extruded liposomes made from archaeobacterial ether lipids. Appl. Microbiol. Biotechnol.42(2–3), 375–384 (1994).
   PubMed Web of Science ®Google Scholar
• Patel GB, Agnew BJ, Deschatelets L, Fleming LP, Sprott GD. In vitro assessment of archaeosome stability for developing oral delivery systems. Int. J. Pharm.194(1), 39–49 (2000).
   PubMed Web of Science ®Google Scholar
• Krishnan L, Sad S, Patel GB, Sprott GD. Archaeosomes induce long-term CD8+ cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help. J. Immunol.165(9), 5177–5185 (2000).
   PubMed Web of Science ®Google Scholar
• Sprott GD, Tolson DL, Patel GB. Archaeosomes as novel antigen delivery systems. FEMS Microbiol. Lett.154(1), 17–22 (1997).
   PubMed Web of Science ®Google Scholar
• Conlan JW, Krishnan L, Willick GE, Patel GB, Sprott GD. Immunization of mice with lipopeptide antigens encapsulated in novel liposomes prepared from the polar lipids of various archaeobacteria elicits rapid and prolonged specific protective immunity against infection with the facultative intracellular pathogen, Listeria monocytogenes. Vaccine19(25–26), 3509–3517 (2001).
   PubMed Web of Science ®Google Scholar
• Krishnan L, Sad S, Patel GB, Sprott GD. Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge. Cancer Res.63(10), 2526–2534 (2003).
   PubMed Web of Science ®Google Scholar
• Gould-Fogerite S, Mannino RJ. Mucosal and systemic immunization using cochleate and liposome vaccines. J. Liposome Res.6, 357–379 (1996).
   Google Scholar
• Gould-Fogerite S, Mannino RJ. Cochleates for induction of mucosal and systemic immune responses. In: Vaccine Adjuvants: Preparation Methods and Research Protocols. O’Hagan DT (Ed.). Humana Press, Inc., NJ, USA, 179–196 (2000).
   Google Scholar
• Papahadjopoulos D, Vail WJ, Jacobson K, Poste G. Cochleate lipid cylinders: formation by fusion of unilamellar lipid vesicles. Biochim. Biophys. Acta394(3), 483–491 (1975).
   PubMed Web of Science ®Google Scholar
• Gherardi MM, Esteban M. Recombinant poxviruses as mucosal vaccine vectors. J. Gen. Virol.86(Pt 11), 2925–2936 (2005).
   PubMed Web of Science ®Google Scholar
• Haneberg B, Herland Berstad AK, Holst J. Bacteria-derived particles as adjuvants for non-replicating nasal vaccines. Adv. Drug Deliv. Rev.51(1–3), 143–147 (2001).
   PubMed Web of Science ®Google Scholar
• Baca-Estrada ME, Foldvari M, Snider Met al. Intranasal immunization with liposome-formulated Yersinia pestis vaccine enhances mucosal immune responses. Vaccine18, 2203–2211 (2000).
   PubMed Web of Science ®Google Scholar
• Harokopakis E, Hajishengallis G, Michalek SM. Effectiveness of liposomes possessing surface-linked recombinant B subunit of cholera toxin as an oral antigen delivery system. Infect. Immun.66(9), 4299–4304 (1998).
   PubMed Web of Science ®Google Scholar
• Kersten GF, Crommelin DJ. Liposomes and ISCOMS as vaccine formulations. Biochim. Biophys. Acta1241(2), 117–138 (1995).
   PubMed Web of Science ®Google Scholar
• Vadolas J, Davies JK, Wright PJ, Strugnell RA. Intranasal immunization with liposomes induces strong mucosal immune responses in mice. Eur. J. Immunol.25(4), 969–975 (1995).
   PubMedGoogle Scholar
• Gould-Fogerite S, Kheiri MT, Zhang Fet al. Targeting immune response induction with cochleate and liposome-based vaccines. Adv. Drug Deliv. Rev.32(3), 273–287 (1998).
   PubMed Web of Science ®Google Scholar
• Betageri GV, Jenkins SA, Parsons DL. Liposome Drug Delivery Systems. Technomic Publishing Co., Inc., PA, USA (1993).
   Google Scholar
• Ausborn M, Nuhn P, Schreier HJ. Stabilization of liposomes by freeze–thaw and lyophilization techniques: problems and opportunities. Eur. J. Pharm. Biopharm.38, 133–139 (1992).
   Web of Science ®Google Scholar
• Bracho G, Lastre M, Campo Jet al. Proteoliposome derived cochleate as novel adjuvant. Vaccine24(Suppl. 2), 30–31 (2006).
   Web of Science ®Google Scholar
• Perez O, Bracho G, Lastre Met al. Novel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular pattern. Immunol. Cell Biol.82(6), 603–610 (2004).
   PubMed Web of Science ®Google Scholar
• Sanders MT, Deliyannis G, Pearse MJ, McNamara MK, Brown LE. Single dose intranasal immunization with ISCOMATRIX™ vaccines to elicit antibody-mediated clearance of influenza virus requires delivery to the lower respiratory tract. Vaccine27(18), 2475–2482 (2009).
   PubMed Web of Science ®Google Scholar
• Hu KF, Lovgren-Bengtsson K, Morein B. Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv. Drug Deliv. Rev.51(1–3), 149–159 (2001).
   PubMed Web of Science ®Google Scholar
• Blocher D, Six L, Gutermann R, Henkel B, Ring K. Physicochemical characterization of tetraether lipids from Thermoplasma acidophilum. Calorimetric studies on miscibility with diether lipids carrying branched or unbranched alkyl chains. Biochim. Biophys. Acta818, 333–342 (1985).
   Google Scholar
• Chen JS, Barton PG, Brown D, Kates M. Osmometric and microscopic studies on bilayers of polar lipids from the extreme halophile, Halobacterium cutirubrum. Biochim. Biophys. Acta352(2), 202–217 (1974).
   PubMedGoogle Scholar
• Szoka F Jr, Papahadjopoulos D. Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu. Rev. Biophys. Bioeng.9, 467–508 (1980).
   PubMedGoogle Scholar
• Krishnan L, Dicaire CJ, Patel GB, Sprott GD. Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: comparison to conventional liposomes and alum. Infect. Immun.68(1), 54–63 (2000).
   PubMed Web of Science ®Google Scholar